Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Complete title: ADVL1212, A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)

Research Study Number ADVL1212
Principal Investigator Julie Park, MD
Phase I

Research Study Description

This phase I trial studies the side effects and the best dose of crizotinib giving together with combination chemotherapy in treating younger patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. Crizotinib may stop the growth of tumor or cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, topotecan hydrochloride, dexrazoxane hydrochloride, doxorubicin hydrochloride, and vincristine sulfate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number ADVL1212
Contact Advanced Therapeutics Study Line
Telephone 206/987-2553

Keywords: Hematologic Malignancies; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Neuroblastoma; Lymphoma, Non-Hodgkin (NHL); Neuroectodermal Tumors, Primitive (PNET); Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Immunoproliferative Disorders; Neuroectodermal Tumors; Lymphoma, Large-Cell, Anaplastic; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Immune System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials